Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.09.2012 | short review | Ausgabe 3/2012

memo - Magazine of European Medical Oncology 3/2012

New drugs for head and neck cancer

memo - Magazine of European Medical Oncology > Ausgabe 3/2012
PhD József Dudás, MD Heinz Zwierzina, MD Dr. Georg Mathias Sprinzl


Worldwide, head and neck squamous cell carcinoma (HNSCC) is the sixth most common neoplasm, and despite advances in therapy, long-term survival in HNSCC patients is poor. Primary surgery followed by chemoradiation, or primary chemoradiation, are the standard treatment options for patients with locally advanced HNSCC. Improvement in the therapy efficiency is being achieved by new derivatives of fluoropyrimidine, novel platinum compounds and targeted antibodies against the epidermal growth factor receptor. Novel targets are being developed involving integrins, cyclooxygenase, and intracellular signaling pathways. Therapeutic results are also reported for immunomodulatory drugs. Patient group stratification based on therapy relevant biomarkers might lead to improved efficiency for antibodies targeted against receptors or for kinase inhibitors.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 3/2012

memo - Magazine of European Medical Oncology 3/2012 Zur Ausgabe